Jul 20, 2019
2019 World Brain Day Takes Aim at Migraine
Jul 13, 2019
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
Jul 12, 2019
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
Jul 12, 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Jul 11, 2019
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
Jul 11, 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
Jun 24, 2019
Theranica Appoints Senior Executives to Lead its New USA Subsidiary
May 22, 2019
World Brain Day takes on the 'Painful Truth' about Migraine in 2019
May 08, 2019
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
May 03, 2019
Upsher-Smith Unveils Educational Resources And Support Tools For Migraine Patients
Feb 27, 2019
eNeura, Inc. Receives FDA Clearance for Acute Treatment and Prevention of Migraine in Children 12 Years of Age and Older
Oct 17, 2018
Express Scripts Offers New Value-Based Program for Migraine
Sep 05, 2018
Headaches Associated With Commuting, Dating And Even Adulting? Now, There's An Excedrin® For That
Jul 11, 2018
Dr. Muhammad Mirza Helps Clients Escape Chronic Migraine Pain Through Botox
Jun 29, 2018
Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine
Jun 29, 2018
SensorRx To Acquire Groundbreaking Mobile Health App "Migraine Coach(TM)"
Jun 27, 2018
Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month
Jun 27, 2018
Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society
Jun 26, 2018
Impel NeuroPharma To Present New Data On INP104 For Treatment Of Acute Migraine At 2018 Annual American Headache Society Meeting
Jun 22, 2018
Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine